REG-Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Lakefront Biotherapeutics reported a strong cash position of €2.24 billion at the end of H1 2026, maintaining year-end guidance of approximately €2.0 billion despite a €733.5 million cash outflow for the Ouro Medicines acquisition. The company initiated a €50 million share repurchase program, signaling financial confidence, while reporting a net profit of €16.6 million compared to a loss in the prior year, driven largely by fair value adjustments.
Key figures
- Eps
- 0.25
- Revenue
- 18600000
- Guidance
- Year-end 2026 cash €1.975B-€2.050B; at least €1.6B remaining after funding portfolio to first gamgertamig approval
- Revenue Yoy
- -87%
- Operational cash burn
- 63600000
- Acquisition cash outflow
- 733500000
- Share repurchase program
- 50000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.